{"drugs":["Famotidine","Heartburn Relief","Pepcid","Pepcid AC"],"mono":{"0":{"id":"222840-s-0","title":"Generic Names","mono":"Famotidine"},"1":{"id":"222840-s-1","title":"Dosing and Indications","sub":[{"id":"222840-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Duodenal ulcer disease:<\/b> acute, 40 mg ORALLY once daily at bedtime or 20 mg ORALLY twice daily<\/li><li><b>Duodenal ulcer disease:<\/b> acute, 20 mg IV every 12 h<\/li><li><b>Duodenal ulcer disease:<\/b> maintenance, 20 mg ORALLY once daily at bedtime<\/li><li><b>Esophagitis - Gastroesophageal reflux disease, Short term treatment:<\/b> 20 to 40 mg ORALLY twice daily for up to 12 weeks<\/li><li><b>Esophagitis - Gastroesophageal reflux disease, Short term treatment:<\/b> 20 mg IV every 12 hours<\/li><li><b>Gastric hypersecretion:<\/b> 20 to 160 mg ORALLY every 6 h<\/li><li><b>Gastric hypersecretion:<\/b> 20 mg IV every 12 h<\/li><li><b>Gastric ulcer, Short term treatment:<\/b> acute, 40 mg ORALLY once daily at bedtime<\/li><li><b>Gastric ulcer, Short term treatment:<\/b> acute, 20 mg IV every 12 h<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> 20 mg ORALLY twice daily for up to 6 wks<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> 20 mg IV every 12 hours<\/li><li><b>Indigestion:<\/b> 10 to 20 mg ORALLY twice daily<\/li><\/ul>"},{"id":"222840-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Duodenal ulcer disease:<\/b> (over 1 y old) 0.5 mg\/kg\/day ORALLY at bedtime or divided twice daily; MAX dose 40 mg\/day<\/li><li><b>Duodenal ulcer disease:<\/b> (over 1 y old) 0.25 to 0.5 mg\/kg IV every 12 h; MAX dose 40 mg\/day<\/li><li><b>Esophagitis - Gastroesophageal reflux disease, Short term treatment:<\/b> (over 1 y old) 1 mg\/kg\/day ORALLY divided twice daily; MAX dose 80 mg\/day; duration based upon response<\/li><li><b>Esophagitis - Gastroesophageal reflux disease, Short term treatment:<\/b> (over 1 y old) 0.25 to 0.5 mg\/kg IV every 12 h; MAX dose 40 mg\/day<\/li><li><b>Gastric ulcer, Short term treatment:<\/b> (over 1 y old) 0.5 mg\/kg\/day ORALLY at bedtime or divided twice daily; MAX dose 40 mg\/day<\/li><li><b>Gastric ulcer, Short term treatment:<\/b> (over 1 y old) 0.25 to 0.5 mg\/kg IV every 12 h; MAX dose 40 mg\/day<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> (over 1 y old) 1 mg\/kg\/day ORALLY divided twice daily up to 40 mg twice daily; MAX dose 80 mg\/day; duration based upon response<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> (3 months to 1 y) 0.5 mg\/kg twice daily as the ORAL suspension for up to 8 wks<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> (less than 3 mths) 0.5 mg\/kg once daily as the ORAL suspension for up to 8 wks<\/li><li><b>Gastroesophageal reflux disease, Short-term, symptom treatment:<\/b> (over 1 y old) 0.25 to 0.5 mg\/kg IV every 12 h; MAX dose 40 mg\/day<\/li><\/ul>"},{"id":"222840-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> (adult) CrCl less than 50 mL\/min, 50% of dose or increase dosing interval to 36-48 hours<\/li><li><b>renal impairment:<\/b> (pediatric) CrCl 30-60 mL\/min\/1.73 m(2), give 50% of dose<\/li><li><b>renal impairment:<\/b> (pediatric) CrCl less than 30 mL\/min\/1.73 m(2), give 25% of dose<\/li><\/ul>"},{"id":"222840-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Duodenal ulcer disease<\/li><li>Esophagitis - Gastroesophageal reflux disease, Short term treatment<\/li><li>Gastric hypersecretion<\/li><li>Gastric ulcer, Short term treatment<\/li><li>Gastroesophageal reflux disease, Short-term, symptom treatment<\/li><li>Indigestion<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Esophagitis, Maintenance<\/li><li>Gastritis<\/li><li>Gastrointestinal hemorrhage<\/li><li>Stress ulcer; Prophylaxis<\/li><li>Urticaria<\/li><\/ul>"}]},"3":{"id":"222840-s-3","title":"Contraindications\/Warnings","sub":[{"id":"222840-s-3-9","title":"Contraindications","mono":"<ul><li>history of hypersensitivity to other H2-receptor antagonists<\/li><li>hypersensitivity to famotidine or any component of product<\/li><\/ul>"},{"id":"222840-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- symptomatic response does not rule out gastric malignancy<\/li><li>Renal:<\/li><li>-- caution in patients with moderate to severe renal insufficiency due to risk of prolonged QT interval  and CNS adverse effects; dose adjustment recommended<\/li><li>Other:<\/li><li>-- use caution in very low birth weight neonates (ie, 401 to 1,500 g) due to increased risk of necrotizing enterocolitis<\/li><\/ul>"},{"id":"222840-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"222840-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"222840-s-4","title":"Drug Interactions","sub":[{"id":"222840-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"222840-s-4-14","title":"Major","mono":"<ul><li>Amiodarone (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Atazanavir (established)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasatinib (established)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Ledipasvir (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Rilpivirine (established)<\/li><li>Sevoflurane (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazoline (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vismodegib (theoretical)<\/li><\/ul>"},{"id":"222840-s-4-15","title":"Moderate","mono":"<ul><li>Cefditoren Pivoxil (probable)<\/li><li>Cefpodoxime Proxetil (probable)<\/li><li>Cyclosporine (probable)<\/li><\/ul>"}]},"5":{"id":"222840-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (1.2% to 1.4%), Diarrhea (1.7%)<\/li><li><b>Neurologic:<\/b>Dizziness (1.3%), Headache (1.3% to 4.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome (very rare), Toxic epidermal necrolysis (very rare)<\/li><li><b>Gastrointestinal:<\/b>Necrotizing enterocolitis in fetus OR newborn<\/li><li><b>Immunologic:<\/b>Anaphylaxis (infrequent), Angioedema (infrequent)<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Neurologic:<\/b>Seizure (rare)<\/li><li><b>Respiratory:<\/b>Interstitial pneumonia (infrequent), Nosocomial pneumonia<\/li><\/ul>"},"6":{"id":"222840-s-6","title":"Drug Name Info","sub":{"0":{"id":"222840-s-6-17","title":"US Trade Names","mono":"<ul><li>Pepcid<\/li><li>Pepcid AC<\/li><li>Heartburn Relief<\/li><\/ul>"},"2":{"id":"222840-s-6-19","title":"Class","mono":"<ul><li>Gastric Acid Secretion Inhibitor<\/li><li>Histamine H2 Antagonist<\/li><\/ul>"},"3":{"id":"222840-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"222840-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"222840-s-7","title":"Mechanism Of Action","mono":"Famotidine, a histamine H(2)-receptor antagonist, primarily inhibits both the concentration and volume of gastric secretion. It does not affect gastric emptying or exocrine pancreatic function, more so, it has little or no effect on fasting or postprandial serum gastrin levels.<br\/>"},"8":{"id":"222840-s-8","title":"Pharmacokinetics","sub":[{"id":"222840-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 1 h to 3 h<\/li><li>Bioavailability: 40% to 45%<\/li><\/ul>"},{"id":"222840-s-8-24","title":"Distribution","mono":"<ul><li>Vd: (0 mo to 1 mo), 1.4 L\/kg +\/- 0.4 L\/kg<\/li><li>Vd: (0 mo to 3 mo), 1.8 L\/kg +\/- 0.3 L\/kg<\/li><li>Vd: (greater than 3 mo to 12 mo), 2.3 L\/kg +\/- 0.7 L\/kg<\/li><li>Vd: (1 y to 11 y), 2.07 L\/kg +\/- 1.49 L\/kg<\/li><li>Vd: (11 y to 15 y), 1.5 L\/kg +\/- 0.4 L\/kg<\/li><li>Vd: (adult), 1.3 L\/kg +\/- 0.2 L\/kg<\/li><li>Protein binding: 15% to 20%<\/li><\/ul>"},{"id":"222840-s-8-25","title":"Metabolism","mono":"<ul><li>Minimal first-pass metabolism<\/li><li>Metabolite: S-oxide<\/li><\/ul>"},{"id":"222840-s-8-26","title":"Excretion","mono":"<ul><li>Renal: (IV), 65% to 70% unchanged<\/li><li>Renal: (Oral), 25% to 30% unchanged<\/li><\/ul>"},{"id":"222840-s-8-27","title":"Elimination Half Life","mono":"<ul><li>2.5 h to 3.5 h<\/li><li>0 mo to 1 mo: 10.5 h +\/- 5.4 h<\/li><li>0 mo to 3 mo: 8.1 h +\/- 3.5 h<\/li><li>greater than 3 mo to 12 mo: 4.5 h +\/- 1.1 h<\/li><li>1 y to 11 y: 3.38 h +\/- 2.60 h<\/li><li>11 y to 15 y: 2.3 h +\/- 0.4 h<\/li><li>adult: 2.83 h +\/- 0.99 h<\/li><li>renal insufficiency: may exceed 20 h<\/li><li>anuric patient: approximately 24 h<\/li><\/ul>"}]},"9":{"id":"222840-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>antacids may be given concomitantly if needed<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>(injection) dilute 2 mL of injection (containing 10 mg\/mL) with 0.9% Sodium Chloride Injection or other compatible IV solution to a total volume of either 5 mL or 10 mL; inject over a period of at least 2 minutes<\/li><li>(infusion) dilute 2 mL of injection with 100 mL of 5% dextrose or other compatible solution and infuse over a 15-30 minute period<\/li><li>compatible IV solutions include Water for Injection, 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, and Lactated Ringer's Injection; injection may form a precipitate at concentrations greater than 0.2 mg\/mL in Sodium Bicarbonate Injection, 5%<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>take at bedtime<\/li><li>(oral disintegrating tablets) use dry hands to remove the tablet from the blister unit, place the tablet on the tongue allowing it to disintegrate, then swallow with saliva; no water is needed<\/li><\/ul><\/li><\/ul>"},"10":{"id":"222840-s-10","title":"Monitoring","mono":"<ul><li>decreased abdominal and\/or gastroesophageal discomfort<\/li><li>endoscopic improvement<\/li><li>CBC<\/li><\/ul>"},"11":{"id":"222840-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Solution: 0.4 MG\/ML, 10 MG\/ML<\/li><li>Oral Powder for Suspension: 40 MG\/5 ML<\/li><li>Oral Tablet: 10 MG, 20 MG, 40 MG<\/li><\/ul><\/li><li><b>Acid Controller<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Acid Reducer<\/b><br\/>Oral Tablet: 10 MG<br\/><\/li><li><b>Good Neighbor Pharmacy Acid Reducer<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Good Sense Acid Reducer<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Heartburn Relief<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Leader Acid Reducer<\/b><br\/>Oral Tablet: 20 MG<br\/><\/li><li><b>Pepcid AC<\/b><br\/><ul><li>Oral Tablet: 10 MG, 20 MG<\/li><li>Oral Tablet, Chewable: 20 MG<\/li><\/ul><\/li><li><b>Pepcid<\/b><br\/><ul><li>Oral Powder for Suspension: 40 MG\/5 ML<\/li><li>Oral Tablet: 20 MG, 40 MG<\/li><\/ul><\/li><li><b>Quality Choice Acid Controller<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Rite Aid Acid Reducer<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><li><b>Rite Aid Famotidine Acid Reducer<\/b><br\/>Oral Tablet: 20 MG<br\/><\/li><li><b>The Medicine Shoppe Acid Control<\/b><br\/>Oral Tablet: 20 MG<br\/><\/li><li><b>TopCare Acid Reducer<\/b><br\/>Oral Tablet: 10 MG, 20 MG<br\/><\/li><\/ul>"},"12":{"id":"222840-s-12","title":"Toxicology","sub":[{"id":"222840-s-12-31","title":"Clinical Effects","mono":"<b>CIMETIDINE AND RELATED DRUGS <\/b><br\/>USES: H2 histamine blockers (or H2 blockers) are available as prescription and non-prescription medications and are used to treat reflux esophagitis, heartburn, and peptic ulcers. PHARMACOLOGY: Antagonist of H2 histamine receptors. This effect decreases gastric acid secretion. TOXICOLOGY: Cimetidine inhibits the cytochrome P450 oxidase enzymes, 1A2, C219, and 2D6, and decreases the metabolism of many other medications. EPIDEMIOLOGY: Exposures to H2 blockers are common, but significant toxicity has not been described. Adverse effects during therapeutic use are rare. MILD TO MODERATE TOXICITY: Mild drowsiness, dizziness or confusion. SEVERE TOXICITY: Severe toxicity is exceedingly rare. CNS depression and hypotension have been reported. ADVERSE EFFECTS: Dry mouth, delirium, and bone marrow suppression have been reported. Bradycardia and conduction effects are rare effects occurring mostly after rapid IV administration.<br\/>"},{"id":"222840-s-12-32","title":"Treatment","mono":"<b>CIMETIDINE AND RELATED DRUGS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. MANAGEMENT OF SEVERE TOXICITY: Intravenous fluids for hypotension, supportive care for CNS depression.<\/li><li>Decontamination: PREHOSPITAL: No prehospital decontamination is recommended. HOSPITAL: No decontamination is warranted in most cases.<\/li><li>Airway management: Rare cases with significant CNS depression may require intubation for airway protection.<\/li><li>Antidote: None<\/li><li>Monitoring of patient: No specific laboratory testing is indicated in most patients. Obtain a basic metabolic screen and serum acetaminophen and salicylate concentrations after deliberate overdose.<\/li><li>Enhanced elimination procedure: Enhanced elimination is not indicated.<\/li><li>Patient disposition: HOME CRITERIA: Patients inadvertent ingestions can be managed at home. All patients with self-harm ingestions should be sent to a healthcare facility for mental health evaluation. OBSERVATION CRITERIA: Patients with deliberate overdose or more than mild symptoms should be referred to a healthcare facility and observed until symptoms resolve. ADMISSION CRITERIA: Patients with significant CNS depression or other symptoms that persist after 6 to 8 hours of observation should be admitted, but this is exceedingly rare. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance if symptoms are more than mild or if the diagnosis is unclear.<\/li><\/ul>"},{"id":"222840-s-12-33","title":"Range of Toxicity","mono":"<b>CIMETIDINE AND RELATED DRUGS<\/b><br\/>TOXICITY: These medications have a large therapeutic window and no more than minimal toxicity is expected even with very large overdoses. THERAPEUTIC DOSE: CIMETIDINE: ADULT: 400 to 1600 mg\/day orally; PEDIATRIC: 20 to 40 mg\/kg\/day orally. FAMOTIDINE: ADULT: 20 to 80 mg\/day orally; PEDIATRIC: 0.5 to 2 mg\/kg\/day orally. RANITIDINE: ADULT: 150 to 300 mg\/day orally; PEDIATRIC: 2 to 10 mg\/kg\/day orally, divided in 2 to 4 doses.<br\/>"}]},"13":{"id":"222840-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause constipation, diarrhea, or dizziness.<\/li><li>Advise patient to take at bedtime.<\/li><li>Patient may take with antacids, if needed.<\/li><\/ul>"}}}